AfterDmab: Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation.

AfterDmab: Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation.

Rationale : Discontinuing denosumab (Dmab) therapy results in increased bone turnover
and a rapid decrease in bone mineral density (“rebound phenomenon”). To test if the duration
of denosumab treatment affects the efficacy of subsequent zoledronate infusion.

Infographic

Reference

Makras P, Appelman-Dijkstra NM, Papapoulos SE, van Wissen S, Winter EM, Polyzos SA, Yavropoulou MP, Anastasilakis AD. The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation. J Clin Endocrinol Metab. 2021 Sep 27;106(10):e4155-e4162.

About the author 

MyEndoConsult

The MyEndoconsult Team. A group of physicians dedicated to endocrinology and internal medicine education.

{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}

Pathophysiology Videos


Videos

  • Learn Basic Physiology
  • Pathophysiology (Advanced Concepts)
  • Clinical Correlates
>